{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bortoletto AS"],"funding":["Eleanor Schwartz Charitable Trust","Baylor College of Medicine Medical Scientist Training Program","NICHD NIH HHS","NHLBI Division of Intramural Research","National Heart, Lung, and Blood Institute","NHLBI NIH HHS","National Institutes of Health","Mike Hogg Fund","NIDDK NIH HHS","Small Business Innovation Research","Robertson Therapeutic Development Fund","National Institute of Child Health and Human Development","NIH HHS"],"pagination":["e2202342"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9731688"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(34)"],"pubmed_abstract":["Type 2 diabetes mellitus (T2D) is a major public health concern and is characterized by sustained hyperglycemia due to insulin resistance and destruction of insulin-producing β cells. One pathological hallmark of T2D is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Monomeric hIAPP is a hormone normally co-secreted with insulin. However, increased levels of hIAPP in prediabetic and diabetic patients can lead to the formation of hIAPP protofibrils, which are toxic to β cells. Current therapies fail to address hIAPP aggregation and current screening modalities do not detect it. Using a stabilizing capping protein, monoclonal antibodies (mAbs) can be developed against a previously nonisolatable form of hIAPP protofibrils, which are protofibril specific and do no"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Human Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes."],"pmcid":["PMC9731688"],"funding_grant_id":["SBIR R43DK125161","R43DK125161","R43 DK125161","T32 HL092332","R01HD099252","R01HD098131","R01 HD098131","R01 HD099252"],"pubmed_authors":["Trout G","Bonito-Oliva A","Kazmi MA","Houser BL","Sakmar TP","Parchem RJ","Weyburne E","Bortoletto AS","Gong J","Graham WV"],"additional_accession":[]},"is_claimable":false,"name":"Human Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes.","description":"Type 2 diabetes mellitus (T2D) is a major public health concern and is characterized by sustained hyperglycemia due to insulin resistance and destruction of insulin-producing β cells. One pathological hallmark of T2D is the toxic accumulation of human islet amyloid polypeptide (hIAPP) aggregates. Monomeric hIAPP is a hormone normally co-secreted with insulin. However, increased levels of hIAPP in prediabetic and diabetic patients can lead to the formation of hIAPP protofibrils, which are toxic to β cells. Current therapies fail to address hIAPP aggregation and current screening modalities do not detect it. Using a stabilizing capping protein, monoclonal antibodies (mAbs) can be developed against a previously nonisolatable form of hIAPP protofibrils, which are protofibril specific and do no","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-07-14T16:57:17.033Z","creation":"2026-06-21T03:07:51.258Z"},"accession":"S-EPMC9731688","cross_references":{"pubmed":["36257905"],"doi":["10.1002/advs.202202342"]}}